Emerging Therapeutic Options for the Management of COPD.

Clin Med Insights Circ Respir Pulm Med

Department of Pharmacy Practice, School of Pharmacy, Northeastern University, Boston, MA, USA.

Published: May 2013

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629926PMC
http://dx.doi.org/10.4137/CCRPM.S8140DOI Listing

Publication Analysis

Top Keywords

management copd
8
emerging therapeutic
4
therapeutic options
4
options management
4
copd
4
copd chronic
4
chronic obstructive
4
obstructive pulmonary
4
pulmonary disease
4
disease copd
4

Similar Publications

Importance: Airway stenosis is a rare but debilitating disorder that significantly degrades the quality of life in affected patients. Treatments are primarily surgical, and disease management lacks established medical therapies. The North American Airway Collaborative held its third symposium at The Johns Hopkins Hospital in Baltimore, Maryland, on April 15, 2024, focused on strategies to advance the care of these patients.

View Article and Find Full Text PDF

Introduction: Off-pump coronary artery bypass graft surgery (OPCAB) has been suggested as superior to on-pump coronary artery bypass graft surgery (ONCAB) in certain high-risk subgroups, but its benefit in patients with chronic obstructive pulmonary disease (COPD) remains controversial. This meta-analysis aimed to evaluate OPCAB versus ONCAB outcomes in COPD patients.

Methods: We followed PRISMA guidelines and searched PubMed, Embase, and the Cochrane Library in August 2024 for studies comparing OPCAB and ONCAB in COPD patients.

View Article and Find Full Text PDF

Objective: The purpose of the study was to examine the association between short-acting beta agonist (SABA), antibiotic and oral corticosteroid (OCS) use and mortality and cardiopulmonary outcomes in chronic obstructive pulmonary disease (COPD).

Design: Retrospective cohort study using administrative health data from 1 April 2011 to 31 March 2020.

Setting: Alberta, Canada.

View Article and Find Full Text PDF

Chronic obstructive pulmonary disease (COPD) is a collection of conditions that cause permanent damage to the lungs. Among a range of treatment options, patients can benefit from pulmonary rehabilitation (PR) programmes involving physical exercises and education.The risk of developing COPD is higher for substance misusers than the general population.

View Article and Find Full Text PDF

Background: Chronic obstructive pulmonary disease (COPD) is a common treatable disease often diagnosed in patients with risk factors after a prolonged period with suggestive symptoms. Our qualitative study aimed to identify barriers to establishing diagnosis in the natural history of this condition.

Methods: An inductive thematic analysis was performed on structured interviews with patients, general practitioners (GPs) and pulmonologists in France.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!